



SAFETY DATA SHEET

1. Identification

Product identifier	LARTRUVO™		
Other means of identification			
Item Code	VL7190, CT2059, VL8926		
LY Number	LY3012207		
Recommended use	Pharmaceutical		
Recommended restrictions	None known.		
Manufacturer/Importer/Supplier/Distributor information			
Manufacturer			
Company name	Eli Lilly and Company		
Address	Lilly Corporate Center Indianapolis, IN 46285 United States		
Telephone	Phone:	+1-317-276-2000	
E-mail	lilly_msds@lilly.com		
Emergency phone number	CHEMTREC:	+1-800-424-9300	

2. Hazard(s) identification

Physical hazards	Not classified.
Health hazards	Not classified.
OSHA defined hazards	Not classified.
Label elements	
Hazard symbol	None.
Signal word	None.
Hazard statement	The mixture does not meet the criteria for classification.
Precautionary statement	
Prevention	Not available.
Response	Not available.
Storage	Not available.
Disposal	Not available.
Hazard(s) not otherwise classified (HNOC)	None known.
Supplemental information	None.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Olaratumab		1024603-93-7	1

Composition comments Remaining components of this product are non-hazardous and/or are present at concentrations below reportable levels.

4. First-aid measures

Inhalation	Call a physician if symptoms develop or persist.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	Get medical attention if symptoms occur.
Most important symptoms/effects, acute and delayed	This mixture contains a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, this substance/preparation is considered unlikely to produce health effects through relevant routes of occupational exposures.

5. Fire-fighting measures

Suitable extinguishing media	Use extinguishing media appropriate for surrounding fire.
Unsuitable extinguishing media	Not available.
Specific hazards arising from the chemical	Not applicable.
Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
General fire hazards	This product is an aqueous mixture which will not burn.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Avoid inhalation of mists or aerosols.
Methods and materials for containment and cleaning up	Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum. Wear appropriate protective equipment and clothing during clean-up.
Environmental precautions	Avoid release to the environment.

7. Handling and storage

Precautions for safe handling	Not available.
Conditions for safe storage, including any incompatibilities	Storage temperature: between 2C and 8C. Do not allow material to freeze.

8. Exposure controls/personal protection

Occupational exposure limits

Lilly (LEG)

Components

	Type	Value
Olaratumab (CAS 1024603-93-7)	TWA (12hrs)	35 ug/m3
	TWA (8hrs)	50 ug/m3

Biological limit values	No biological exposure limits noted for the ingredient(s).
Appropriate engineering controls	Open handling is not recommended. Use appropriate control measure (i.e. fume hood, ventilated enclosure, local exhaust ventilation) to maintain airborne levels below occupational exposure level (OEL).

Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with side shields recommended. If splash potential or dusty operations, wear goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Other

While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear impervious gloves and body covering (i.e. lab coat) to minimize skin contact.

Respiratory protection If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an approved respirator with sufficient protection factor to control exposure below the OEL.

Thermal hazards Not available.

General hygiene considerations Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This mixture contains a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

9. Physical and chemical properties

Appearance	Clear to slightly opalescent liquid.
Physical state	Liquid.
Form	Not available.
Color	Colorless to Light yellow
Odor	Not available.

Odor threshold	Not available.
pH	5.3 - 5.7
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	Not available.
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Soluble
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Explosive properties	Not explosive.
Oxidizing properties	The substance or mixture is not classified as oxidizing.

10. Stability and reactivity

Reactivity	Not water reactive.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	Hazardous polymerization does not occur.
Conditions to avoid	None under normal conditions.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	No hazardous decomposition products are known.

11. Toxicological information

Information on toxicological effects

Acute toxicity	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	
Respiratory sensitization	Due to lack of data the classification is not possible.
Skin sensitization	Due to lack of data the classification is not possible.
Germ cell mutagenicity	This substance is a monoclonal antibody. It does not possess mutagenic potential. Mutagenicity testing has not been conducted. Based on available data, the classification criteria are not met.
Carcinogenicity	Not listed by IARC, NTP, ACGIH or OSHA. Due to lack of data the classification is not possible.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity	Studies of PDGFs and PDGFRs in animal development have indicated that disruption of PDGFR alpha signaling may impair gastrulation and the development of the cardiac and cranial neural crest, gonads, lung, intestine, skin, central nervous system, and skeleton. Based on available data, the classification criteria are not met.
Specific target organ toxicity - single exposure	Based on available data, the classification criteria are not met.
Specific target organ toxicity - repeated exposure	No adverse effects reported in animals administered 75 mg/kg intravenously weekly for 39 weeks. Based on available data, the classification criteria are not met.
Aspiration hazard	Not applicable.
Further information	This mixture contains a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

12. Ecological information

Ecotoxicity	Not expected to be harmful to aquatic organisms.
Persistence and degradability	Not available.
Bioaccumulative potential	Not available.
Mobility in soil	Not available.
Other adverse effects	Not available.

13. Disposal considerations

Disposal instructions	Dispose in accordance with all applicable regulations.
------------------------------	--

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not available.

15. Regulatory information

US federal regulations This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date 11-03-2016

Revision date 02-06-2019

Version # 04

List of abbreviations LEG: Lilly Exposure Guideline.

TWA: Time Weighted Average

Disclaimer

This document provides available information relevant to the handling of the experimental material identified above. Some of the information contained herein is preliminary, and some sections may contain opinions based on available scientific information. All of the information is offered with the good faith belief that it is accurate, but this safety data sheet does not constitute a warranty of any kind, express or implied. This document has been made available so that proper protective measures can be taken by persons who may be exposed to the material during pre-market research and development activities. In the event of any adverse incident associated with this material, the safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel.

For additional information contact:
Eli Lilly and Company
Hazard Communication
+1-317-651-9533